What is CorMedix's stock-based comp?

CorMedix (CRMD) reported stock-based comp of $4.58M in Q1 2026.

How has CorMedix's stock-based comp changed year-over-year?

CorMedix's stock-based comp increased by 30.9% year-over-year, from $3.5M to $4.58M.

What is the long-term trend for CorMedix's stock-based comp?

Over 4 years (2021 to 2025), CorMedix's stock-based comp has grown at a 28.7% compound annual growth rate (CAGR), from $5.04M to $13.83M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

CorMedix CRMD Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

Merck & Co.MRK

$185M-5.1%

Merit Medical SystemsMMSI

$8.96M-1.3%

ITG

Integer HoldingsITGR

$6.66M-3.2%

IAR

Integra LifeSciencesIART

$5.17M+176%

Emergent BiosolutionsEBS

$1.9M+26.7%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$605.65M-34.4%

P/E3.4×—

P/S1.5×-9.6×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CorMedix's stock-based comp?: CorMedix (CRMD) reported stock-based comp of $4.58M in Q1 2026.
How has CorMedix's stock-based comp changed year-over-year?: CorMedix's stock-based comp increased by 30.9% year-over-year, from $3.5M to $4.58M.
What is the long-term trend for CorMedix's stock-based comp?: Over 4 years (2021 to 2025), CorMedix's stock-based comp has grown at a 28.7% compound annual growth rate (CAGR), from $5.04M to $13.83M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.